

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC

# FINANCIAL REPORT FOR THE YEAR 2013

# PREPARED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS

Original financial report in LVL expressed in EUR. Exchange rate 0,702804 EUR/LVL.

Rīga 2014

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC TABLE OF CONTENTS

	PAGE
INFORMATION ABOUT PARENT COMPANY	3
COUNCIL AND BOARD OF THE GROUP	4
MANAGEMENT REPORT	5 – 6
STATEMENT OF MANAGEMENT'S RESPONSIBILITIES	7
FINANCIAL STATEMENTS	8 – 12
STATEMENT OF FINANCIAL POSITION	8 – 9
COMPREHENSIVE INCOME STATEMENT	10
STATEMENT OF CHANGES IN EQUITY	11
STATEMENT OF CASH FLOWS	12
NOTES TO THE FINANCIAL STATEMENTS	13 – 22
INDEPENDENT AUDITOR'S REPORT	23

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC INFORMATION ABOUT PARENT COMPANY

COMPANY NAME: LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC

**LEGAL STATUS:** Joint stock company

**REGISTRATION:** Registered in Latvian Register of Enterprises at 27.08.2004.

Registration Number: 40003306807

**LEGAL ADDRESS:** 23, Patversmes str., Riga, LV - 1005, Latvia

**SHARES** 800 000 public registered shares with face value 1,00 LVL

ISIN code:LV0000100741

1 200 registered shares listed in the register of the Board

MAJOR SHAREHOLDERS: Ilze Birka 17.5%

Mārtiņš Birks 17.5% Ilze Aizsilniece 11.4% Guna Švarcberga 10.4%

Jānis Birks 8.7%

Adomas Navickas 6.4%

**SUBSIDIARY COMPANY:** "Juras medicIna" Ltd. - 100.00%

Registration Number: 40003171237

28 December 1993

5 Vecmilgravja str., Linija 28, Riga, LV 1015

**REPORTING PERIOD:** 1 January 2013 - 31 December 2013

**AUDITORS NAME AND ADDRESS:** System audit Ltd.

Licence No.53 Matisa str. 19-6 Riga, LV-1001

Latvia

Certified auditor in charge:

Irina Saksaganska Certificate No.41

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC COUNCIL AND BOARD OF THE GROUP

# Council of the company

From April 28, 2010 till the financial statements signing day

Position	Name
Chairman of the Council	Martins Birks
Member of the Council	Viesturs Shilinsh
Member of the Council	Ineta Gadzjus
Member of the Council	Jevgenijs Kalejs
Member of the Council	Uldis Osis

# **Board of the company**

From August 18, 2009 till the financial statements signing day

Position	Name
Chairman of the Board	Janis Birks
Member of the Board	Marta Aizsilniece
Member of the Board	Andris Vigants

#### LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC

#### MANAGEMENT REPORT

#### Type of activity

JSC Latvian maritime medicine centre (LJMC) is a certified, high level and all available private medical authority that consists of: Sarkandaugava outpatient health care center Patversmes 23, Riga, Central Hospital Patversmes 23 Riga, Vecmīlgrāvis hospital and Ziemeļu diagnostic Center Vecmīlgrāvia 5. Līnija 26, Riga, Vecmīlgrāvis primary health care center Melīdas 10, Riga. In 2013 average number of LJMC employees is 355.

2013 LJMC is included in the LR Health inspection approved list of agencies providing medical tourism services i.e. LJMC services as a trusted partner, and it gives an idea about the Latvian healthcare system as a whole, because it includes only those medical institutions that are registered in the register of medical institutions for at least 3 years and over the last three years, the medical institution has been in control.

On March 2013 Joint-stock company Latvijas Jūras medicīnas centrs "Ziemeļu diagnostikas centrs" received a quality certificate ISO 9001:2008 in functional diagnostics and radiology from DVN Certification OY/AB, Finland. This certificate is valid till March 14, 2016. The work on the initiation of ISO quality standards in the other structural units continues

LJMC have concluded cooperation agreements with all the health insurance companies.

LJMC shares are quoted on "NASDAQ OMX Riga" in the second list. Full information about the company is provided: www.ljmc.lv

#### Activity in the reporting year and future development

2013 LJMC completed an ambitious 3-year investment project of 1.6 million LVL. Investment project entailed two major sections: the Medical Center's old building complex renovation and redevelopment of the areas adjacent to the modern medical standards, and secondly, investment in new equipment, medical equipment, and to raise the competitiveness of the Baltic market, attracting medical patients from both the EU and the Baltic and offering high quality medical examinations. The investment project was launched with the support from ERAF.

Of the investment project tasks was to put together the LJMC family doctor practices, thus was created the modern family physician practice Center, located in the LJMC Riga Northern District at Vecmīlgrāvī. Since a new family doctor practices LJMC Center was created number of new customers increased by 25%.

One of the goals of Building renovation project was to create a new ambulatory health care centre in Sarkandaugava Patversmes 23, earlier provided inpatient health care services. Redirection of inpatient health care service to ambulatory health care service improves the future effectiveness, maximizes LJMC resources and provides better medical care to patients.

In May 2013 LJMC won a tender regarding the right to provide medical care with Paul Stradins Clinical University Hospital patients for 1 years.

As one of 2014 development directions LJMC focuses on attracting foreign patients. LJMC combines excellent doctors in Latvia and a knowledgeable medical staff, so the quality of the medical study is deep and competitive both in and out of Latvia. It resulted in increasing number of foreign patients, as well as including LJMC in the official medical tourism service provider register kept by the LR Health inspection. LJMC in 2013 mainly attracted medical tourists from EU. To attract more new foreign and local patients, LJMC in 2014 has set the investment objectives: implementation of innovative solutions in the medical service, staff training in patient care, continue state policy on the hospital redirection, providing investment in Vecmīlgrāvis hospital.

#### Financial performance

In 2013 the audited financial statement has been prepared in accordance with the European Union accepted International Financial Reporting Standards (IFRS), based on the principle of a continuing business. The report is prepared in Latvian lats and euro. Currency exchange rate EUR/LVL 0.702804.

2013 LJMC has worked according to the budget: revenue plan has been fulfilled for 98.8% and expenditure is met by 101.5%.

#### LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC

#### MANAGEMENT REPORT

LJMC financial indicators for the last 3 years:

·	2013	2012	2011
Net sales (milj. EUR)	5,08	5,39	5,01
Investment in long-term asset (milj. EUR)	0,17	0,70	1,61
Assets at the end of the year (milj. EUR)	4,98	5,32	5,61
Loss after taxes (EUR)	-294,853	-76,745	-121,492
EBITDA (EUR)	366,621	625,733	472,924
Liquidity (CR)	3.60	2.98	2.01
Credit rate (DR)	0.18	0.18	0.20
Return on equity (ROE), %	-7,6%	-1,9%	-2,9%
Loss after taxes on share (EUR)	-0.37	-0.10	-0.16
LJMCshare market price at the end of the year(EUR)	2.13	2.70	1.78

The LJMC audited financial statements 2013 shows that LJMC loss before taxes was EUR 310,227. The loss was planned because the company sells intensive investment policy to focus on the company's competitiveness and profitability in the future. In 2014 LJMC planned investment is expected to amount to EUR 430 000.

#### Risk management

LJMC potential financial risk management sought to reduce the negative impact on the financial position of the company, the exercise of control and analysis package.

Exposed to the credit risk of financial assets consist mainly of cash, trade receivables and other debtors

Credit risk management carried out regular customer LJMC control procedures and measures for recovering of debts, thus ensuring timely identification and resolution of problems.

LJMC followed prudent liquidity risk management, ensuring appropriate resources are made available for settlement of obligations within the time limits laid down. LJMC does not use borrowed funds.

# **Important Events after the Balance Sheet Date**

Along with LR accession to the European Economic and Monetary Union 01.01.2014. LJMC action will not be subject to the exchange rate of the euro at risk.

The contract has been concluded with a national health service of the country paid the provision of medical services, to the extent provided for in the 2014 budget.

# Proposal of the Management Board to cover losses

The Management Board proposes LJMC 2013 loss to be covered by the previous year the accumulated profit.

Chairman of the Management Board Jānis Birks

Member of the Management Board Marta Aizsilniece

Member of the Management Board Andris Vigants

Rīga, 2014. gada 20. marts

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC STATEMENT OF MANAGEMENT'S RESPONSIBILITIES

Financial statements are prepared to the best of our knowledge, in accordance with International Financial Reporting Standards adopted by the European Union. These financial statements give a true and fair view of the financial position of the Company and of its financial perfomance for the period ended 31 December 2013 in all essential aspects. In preparing those financial statements, management:

- selected suitable accounting policies and then apply them consistently;
- made judgments and estimates that are reasonable and prudent;
- prepared the financial statements on the going concern basis to presume that the Group will continue in business.

The Management Board is responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time to ensure that financial statements drawn up from them comply with International Financial Reporting Standards as adopted by EU. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The management Board is also responsible for operation of the Company in compliance with the legislation of the Republic of Latvia.

Chairman of the Board Janis Birks

Member of the Board Marta Aizsilniece

Member of the Board Andris Vigants

Riga, 20 March, 2014.

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC STATEMENT OF FINANCIAL POSITION AS OF 31 DECEMBER 2013 AND 31 DECEMBER 2012

	December 31, 2013	December 31, 2012	Notes	
ASSETS	EUR	EUR		
Long-term investments:	<u>-</u>	<del></del>		
Intangible assets:				
Concessions, patents, licenses, trademarks and similar rights	19,707	21,675	2	
Total intangible assets	19,707	21,675		
Fixed assets				
Land and buildings	2,215,991	2,449,399		
Technological equipment and machines	829,713	1,112,950		
Other fixed assets and fixtures	65,650	54,285		
Fixed assets add-ons (EU fonds)	-	-		
Advance payments for fixed assets	-	4,727		
Total fixed assets	3,111,354	3,621,361	2	
Long-term financial assets				
Investment in affiliates	288,472	285,972	3	
Investment in associates	141,624	141,624	4	
Total financial assets:	430,096	427,596		
Total long-term investments:	3,561,157	4,070,632		
Current assets:				
Invetories				
Raw materials	84,688	97,285	5	
Advance payments for goods	185	391	6	
Total Inventories	84,873	97,676		
Debtors:				
Trade receivables	164,235	110,406	7	
Other receivables	30,634	9,501	8	
Deffered expenditure	3,681	3,960	9	
Total debtors	198,550	123,867		
Cash funds	1,131,288	1,030,459	10	
Total current assets	1,414,711	1,252,002		
TOTAL ASSETS	4,975,868	5,322,634		

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC STATEMENT OF FINANCIAL POSITION AS OF 31 DECEMBER 2013 AND 31 DECEMBER 2012

	December 31, 2013	December 31, 2012	Notes
LIABILITIES	EUR	EUR	
Equity capital:			
Share capital	1,138,297	1,138,297	11
Long-term financial assets revaluation reserve Reserves:	790,654	929,364	
Reserves provided by the Articles of Association	45,522	45,522	
Retained earnings	1,888,343	2,020,007	
Total shareholders' equity	3,862,816	4,133,190	
Provisions for liabilities and charges:			
Provisions for vacations	107,711	69,176	
Deferred tax provisions	111,256	151,109	23
Total provisions	218,967	220,285	
Long-term Liabilities:			
Deferred income	501,577	549,127	12
Total Long-term Liabilities:	501,577	549,127	
Short-term Liabilities:			
Advance payments	5,783	18,270	13
Trade Payables	87,764	89,770	14
Deferred income	47,551	47,551	15
Taxes and social security payments	113,956	121,343	16
Other payables	137,454	143,098	17
Total Short-term Liabilities:	392,508	420,032	
Total liabilities	894,085	969,159	
TOTAL EQUITY, PROVISIONS AND LIABILITIES	4,975,868	5,322,634	

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC COMPREHENSIVE INCOME STATEMENT FOR THE YEARS ENDED 31 DECEMBER 2013 AND 31 DECEMBER 2012

	2013, 12 month period EUR	2012, 12 month period EUR	Notes	
Net sales	5,081,474	5,391,741	18	
Cost of goods sold	(5,109,134)	(5,131,981)	19	
Gross profit or loss	(27,660)	259,760		
Administrative expenses	(458,992)	(473,737)	20	
Other operating income	177,738	149,830	21	
Other operating expenses	(1,313)	(6,477)	22	
Interest income and similar income	-	38		
Income from investments in subsidiaries and associates	-	11,022	23	
Profit (loss) before taxes	(310,227)	(59,564)		
Corporate income tax	15,374	(17,181)	24	
NET PROFIT OR LOSS	(294,853)	(76,745)		
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	(294,853)	(76,745)		
Number of shares	1,138,297	1,138,297		
Loss per Share (EPS)	-0.26	-0.07		
ROE	-7.6%	-1.9%		

### LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC STATEMENT OF CHANGES IN EQUITY FOR THE YEARS ENDED 31 DECEMBER 2013 AND 31 DECEMBER 2012

	Share capital EUR	Reserves provided by the Articles of Associatio n	Properties revaluation reserve EUR	Undistribut ed profit EUR	Total EUR
At 31 December 2011	1,138,297	45,522	1,068,068	1,933,570	4,185,457
Depriciation of revaluation surplus	-	-	(163,182)	163,182	-
Deffered tax on revaluation surplus	-	-	24,478	-	24,478
Total comprehensive income for the year	-	-	-	(76,745)	(76,745)
At 31 December 2012	1,138,297	45,522	929,364	2,020,007	4,133,190
Depriciation of revaluation surplus	-	-	(163,189)	163,189	-
Deffered tax on revaluation surplus	-	-	24,479	-	24,479
Total comprehensive income for the year	-	_	-	(294,853)	(294,853)
At 31 December 2013	1,138,297	45,522	790,654	1,888,343	3,862,816

# LATVIJAS JŪRAS MEDICĪNAS CENTRS JSC STATEMENT OF CASH FLOWS FOR THE YEARS ENDED 31 DECEMBER 2013 AND 31 DECEMBER 2012

	2013	2012	NOTES
	EUR	EUR	
Cash flows from operating activities			
Net income before tax	(310,227)	(59,564)	
Adjustments:			
a) depreciation of fixed assets	676,848	685,297	2
b) provisions	38,536	(50,492)	
c) loss (gain) on sale of fixed assets	(3,695)	582	21, 22
d) interest income	-	(38)	
e) Deferred income	(47,551)	· -	19
2. Changes in operating current assets and liabilities	353,911	575,785	
Corrections	,	,	
a) receivables	(74,684)	111,851	
b) inventory	12,803	(2,150)	
c) current liabilities	(27,523)	(383,495)	
3. Gross operating cash flow	264,507	301,991	
4. Paid corporate income tax	-	(5,080)	17
5. Net cash used in operating activities	264,507	296,911	
II. Cash flow used in investment activities			
1. Purchase of shares of subsidiaries	(2,500)	(501.202)	
2. Purchase of fixed assets	(167,533)	(701,283)	2
3. Income from sale of fixed assets	6,355	531	• •
4. Received interest	-	38	20
5. Net cash from investment activities	(163,678)	(700,714)	
III. Cash flows used in financing activities			
1. Settlement of loans	-	223,889	
2. Net cash from financing activities	-	223,889	
IV Not in average (decreases) in	100 020	(170.014)	
IV. Net increase (decrease) in cash	100,829 1,030,459	(179,914)	
V. Cash at the beginning of the period VI. Cash at the end of the period	1,131,288	1,210,373	
vi. Cash at the end of the period	1,131,288	1,030,459	

#### 1. GENERAL INFORMATION

"Latvijas Juras Medicinas Centrs" is a joint-stock company (the Company) incorporated in the Republic of Latvia on 27 August 1996.

The Company's main activity is health care services.

#### 2. ACCOUNTING PRINCIPLES

#### Basis of preparation of financial statements

The financial statements have been prepared in accordance with the International financial reporting standards adopted by the European Union. Enclosed financial statements are prepared in the national currency of Latvia, the lats (LVL).

#### Foreign currency

Transactions denominated in foreign currencies are converted into Lats by the official exchange rate of the Bank of Latvia at the date of transaction. Monetary assets and liabilities are converted by the excannge rate of the Bank of Latvia as on the date of statements of financial position.

The applicable rate used for the principal currencies were the follows:

	December 31, 2013	December 31, 2012
EUR	0.702804	0.702804
USD	0.535	0.544

Gain or loss on conversion is posted to the statement of comprehensive income on the official exchange rate of the Bank of Latvia as of the statement of financial postion date and recognized in the period when they incurred.

Exchange differences rising on the settlement of monetary items are recognized in the period in which they arise.

#### Cash and cash equivalents

Cash includes cash on hand and demand deposits with credit institutions. The statement on cash flow is prepared using indirect method, making adjustments affecting the net profit reconciling with the changes in cash during the year.

The statement on cash flows is prepared according to IAS 7.

#### Trade receivables

Trade receivables are stated at their net realizable value. Trade receivables represent the gross balance due from customers less provision, if any, for doubtful accounts receivable. Provision for doubtful accounts receivable at the balance sheet date represents the estimated amounts of probable losses that might have been incurred at the statement of financial position date based on individual evaluation of each debtor.

#### **Inventory**

Inventories are stated at the lower of cost or market, using FIFO method.

#### Fixed assets

Fixed assets excluding real estate are stated at historical cost, less accumulated depreciation. The cost of the item comprises its purchase price, including import duties and any directly attributable costs of bringing the asset to working condition for intended use. The cost of self-constructed asset is determined using the same principles as for an acquired asset. Only assets with its useful life more than one year are capitalized. Depreciation is calculated based on the historical cost.

Separate accounts are used for assets acquired by EU funding.

Repair and maintenance costs are expensed when incurred. Capital expenditures such as refurbishment of buildings and improvements to structural elements are recognized as an asset if the expenditures improve the condition of the asset beyond its original estimated life.

Land and buildings (real estate) are accounted according to the revaluation model, recognized at the fair value determined from market-based evidence. Buildings are revaluated as on 31.12.2011 based on the cadastral value as fair value. Accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount restated to the revalued amount of the asset. Depreciation is calculated based on the revalued amount. The depreciation charge for each period is recognised in the statement of income.

The increase (decrease) in the value of buildings and constructions is reflected in the Statement of comprehensive income under "Gains (losses) from revaluation of properties". Revaluation decreases are charged first against the revaluation surplus in equity related to the specific asset, and any excess against profit or loss.

Depreciation is provided on all fixed assets based on historical cost. Depreciation on fixed assets are computed using the straight-line method over the estimated average useful lives:

Buildings: 20 years
Revaluated part of the buildings
Machinery and equipment: 3 years
Other fixed assets: 5 years

For tax purposes, depreciation on tangible fixed assets is calculated under the double declining balance method over the period established in accordance with prevailing tax legislation.

#### Investments in associates

Investments in associates are initially recognized at the cost.

## Revenue recognition

Sales of goods are recognized when goods are delivered and title has passed.

#### **Dividends**

Dividends are recognized as liabilities in the Company financial statements after the Company shareholders made a decision to pay.

#### **Deferred income**

Government grants are accounted according to IAS 20. A government grant is recognised only when there is reasonable assurance that the Company will comply with any conditions attached to the grant and the grant will be received.

The grant is recognised as income in the statement statement of profit or loss and other comprehensive income the period necessary to match them with the related costs, for which they are intended to compensate, on a systematic basis.

Government grants related to assets, including non-monetary grants, are accounted for at fair value, presented as deferred income in the statement of financial position, which are recognised as income from the different exercises on a systematic and rational, over the life of the related assets.

# Property revaluation surplus

The revaluation surplus is included in other comprehensive income and accrued amount is reflected in equity under the heading "Investment revaluation reserve". According to IASs 16, p.41, the revaluation surplus included in equity is transferred directly to retained earnings. The surplus transferred is the difference between depreciation based on the revalued carrying amount of the asset and depreciation based on the asset's original cost. Transfers from revaluation surplus to retained earnings are not made through profit or loss.

#### **Taxation**

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in opinion of management, it is more likely than not that some proportion or all deferred tax assets will not be realized.

Deferred tax on revaluation surplus is reflected in the Statement of other comprehensive income.

#### Risk Management

The Management Board is responsible for setting up risk management guidelines and risk monitoring.

The Company has identified the major risk factors and developed policies and mechanisms to control these factors. The major risks are defined as:

Market risk: a country's economic deterioration, changes in the public and the insurer health care and its financing policy, competition, changes in utility tariffs, etc. can significantly affect the demand for Groups services and its profitability.

Operational risk: The possibility of suffering losses caused by inadequate or failed internal pace of the medical treatment process, actions of staff or systems, or external events impact. Patient dissatisfaction with the quality of medical services, treatment process organization or staff attitudes in the long term can lead to a fall in income and even financial claims.

Credit Risk: The inability of insurance companies and patients to pay for the services in time and in full amount.

Liquidity risk: unable to meet the legally enforceable requirements without major damage and inability to cope with unplanned changes in Groups resources and / or market conditions related to the fact that it does not have sufficient liquid assets.

Risk control mechanisms include: appropriate risk policies, investment planning, cash flow planning, budgeting and control, liquidity control, the medical treatment process organization and control, sanitary compliance control, staff skill development, implementation of advanced technologies, employee involvement in risk assessment and control.

#### 2. TOTAL FIXED ASSETS AND OTHER INTANGIBLE ASSETS

As on 31 December 2013 and 31 December 2012 fixed and intangible assets are composed as follows:

EUR	Intangible assets	Land	Buildings and structures and perennial plants	Machinery and equipment	Other fixed assets	Fixed assets add-ons (EU fonds)	Advance payments for fixed assets	Total
Historical cost								
At 31 December								
2011	37,531	602,383	3,053,975	3,590,343	478,870	585,610	8,584	8,357,296
Additions	27,079	-	976,554	246,968	40,149	(585,610)	(3,857)	701,283
Transfers	-	-	-	-	-	-	-	-
Disposals	-	-	-	(44,603)	(18,772)	-	-	(63,375)
At 31 December								
2012	64,610	602,383	4,030,529	3,792,708	500,247	-	4,727	8,995,204
Additions	11,347	-	27,279	87,115	46,519	-	(4,727)	167,533
Disposals or change								
in classification	(3,917)		(1,851)	(196,925)	(42,812)		-	(245,505)
At 31 December 2013	<b>53</b> 0.40	(02.202	4 055 055	2 (02 000	502.054			0.015.000
2013	72,040	602,383	4,055,957	3,682,898	503,954	-	-	8,917,232
Accumulated depreci	ation							
At 31 December								
2011	36,489	-	1,943,426	2,326,499	422,719	-	-	4,729,133
Charge for the year	6,446	-	76,905	397,862	40,902	-	-	522,115
Charge for the period								
for revaluated fixed assets			162 192					162 102
	-	-	163,182	- (44.602)	(17.650)	-	-	163,182
Disposals At 31 December	-	-	-	(44,603)	(17,659)	-	-	(62,262)
2012	42,935		2,183,513	2,679,758	445,962			5,352,168
Charge for the year	13,315	_	97,494	370,311	32,535	_	_	513,655
Charge for the period	15,515		77,77	370,311	32,333	_	_	313,033
for revaluated fixed								
assets	_	-	163,193	-	-	_	_	163,193
Disposals or change								
in classification	(3,917)	-	(1,851)	(196,884)	(40,193)	-	-	(242,845)
At 31 December								
2013	52,333	_	2,442,349	2,853,185	438,304	-	-	5,786,171
Net book value								
At 31 December		<0.0 a.o.				<b>-0-</b> (10	0 = 0.4	
2011	1,042	602,383	1,110,549	1,263,844	56,151	585,610	8,584	3,628,163
At 31 December 2012	21 (75	(02.202	1 0 47 01 7	1 112 050	E 4 305		4 707	2 (42 02(
At 31 December	21,675	602,383	1,847,016	1,112,950	54,285	-	4,727	3,643,036
2013	19,707	602,383	1,613,608	829,713	65,650	_	_	3,131,061
	17,101	002,000	1,010,000	027,113	03,030			5,151,001

The balance value of the buildings excluding reevaluation adjustments as on 31-12-2013 is 402.054 EUR.

## 3. INVESTMENT IN AFFILIATES

"Juras medicIna" Ltd 100.00% 288,472  Total 288,472	2012 EUR 285,972 285,972
4. INVESTMENT IN ASSOCIATES	
	2012 EUR 141,624 141,624
5. RAW MATERIALS	
Pharmaceutical 71,684 Medicine in departments 12,895 Other materials 109 Total 84,688	2012 EUR 79,803 17,124 358 97,285
6. ADVANCE PAYMENTS FOR GOODS	
	2012 EUR 391 391
7. TRADE RECEIVABLES	
2013	2012
Riga's health department 70,691 P.Stradiņa klīniskā universitātes slimnīca 24,996 Insurance BTA SE 10,444 Gjensidige Baltic 10,195 Compensa Life Vienna Insurance group 5,488 Ergo Latvija AAS 4,485 IF Latvija AAS 4,441 SEESAM Latvija 3,849 Skruvite GS 3,815 Balta AAS 2,331 Rīgas Pshiatrijas un Narkoloģijas centrs 1,750 Latvijas dzelzcels AS 1,722 Latvijas Universtate 1,043 Akrona 12 905 Olla M Ltd. 885 Ministry of Interior – health and social	9,933 24,865 29,320 4,963 1,384 3,392 2,484 2,942 3,950 680 - 1,722 4,172 4,812 1,652

7. TRADE RECEIVABLES(continued)				
,	2013		2012	
	EUR		EUR	
Balva AAS	795		1,030	
Grinko Genadijs	711		1,423	
Baltijas apdrosinasanas nams	660		1,614	
Biogen Idec Ltd.	-		178	
Other customers	22,121		12,633	
Bad debt provisions	(7,960)	_	(3,950)	
Total	164,235	=	110,406	
8. OTHER RECEIVABLES				
	2013		2012	
	EUR		EUR	
Short-term loan to Juras medicina Ltd. (annual	1			
interest 5.3%)	14,752		-	
Taxes overpaid (note No.15)	5,111		5,111	
VAT for unpaid invoices	4,032		2,906	
Venden Ltd.	282		282	
Advances to employees	58		128	
Other receivables	6,399		1,074	
Total	30,634	_	9,501	
9. DEFFERED EXPENDITURE				
	2013		2012	
	EUR		EUR	
Assurance	3,681		3,960	
Total	3,681	=	3,960	
10. CASH FUNDS				
100 012011 1 01 (20	2013		2012	
	EUR		EUR	
Cash in banks				
Swedbank LVL	913,854		812,857	
Citadele bank LVL	64,405		25,697	
Unibank Ridzenes branch LVL	46,999		33,759	
Unibanka Ridzenes branch EUR	43,117		43,117	
Swedbank Multi-currency Account	39,438		22,399	
DNB Nord LVL	14,508		4,826	
Swedbank Card	4,566		5,125	
State cash LVL	16		73,558	
Cash on hands	4,385	-	9,121	
Total	1,131,288	=	1,030,459	
11. SHARE CAPITAL	201	12	2012	
	2013 Number of		2012 Number of	
Shareholders:	Number of shares	Share %	Number of shares	Share %
Ilze Birka	199,202	17.50%	199,202	17.50%
Martins Birks	199,202	17.50%	199,202	17.50%
Ilze Aizsilniece	130,285	11.45%	130,285	11.45%
Guna Shvarcberga	117,980	10.36%	117,980	10.36%
Janis Birks	98,629	8.66%	96,731	8.50%
Adomas Navickas	72,317	6.35%	56,215	4.94%
Other shareholders (shares less than 5%)	320,682	28.17%	338,682	29.75%
Saler situremorates (situres ress tituli 3/0)	320,002	20.1//0	330,002	47.13/

Total

Share equity

100.00%

1,138,297

1,138,297

100.00%

1,138,297

1,138,297

12. DEFERRED INCOME					
		2013		2012	
		EUR		EUR	
ERDF project reimbursement		501,577		549,127	
Total		501,577	-	549,127	_
10		301,577	=	010,127	=
13. ADVANCE PAYMENTS					
		2013		2012	
		EUR		EUR	
VEK advance payment (94)		4,169		4,169	
Latvijas aptieka Ltd.		1,423		1,423	
Nacionālais veselības centrs		, -		12,475	
Other advances for treatment of emp	plovees	191		203	
Total	p )	5,783	-	18,270	
1000		2,700	=	10,270	=
14. TRADE PAYABLES					
		2013		2012	
		EUR		EUR	
MedilinkLtd.		14,930		-	
Latvenergo Rigas elektrotikls		10,397		11,192	
Sistēmu Audits Ltd.		8,608		6,022	
Latvijas Gaze		4,956		-,·	
Zītari Ltd		2,639		3,637	
Rigas Udens		1,104		978	
Academic histologic laboratory		322		152	
Tradintek Ltd.		322		54,386	
Other suppliers		44,808		13,403	
Total		87,764	-	89,770	
Total		67,704	=	02,770	=
15. DEFERRED INCOME		2013		2012	
		EUR			
EDDE				EUR	
ERDF project reimbursement		47,551	-	47,551	_
Total		47,551	=	47,551	=
16. TAXES AND SOCIAL SECURITY PAYMENTS					
	As of 31- 12-12	Calculated	Paid	Returned	As of 31-12- 13
	EUR	EUR	EUR	EUR	EUR
Value added tax	1,389	32,131	(31,885)	-	1,635
Social insurance	76,293	879,335	(883,272)	-	72,356
Personal income tax	43,295	479,515	(483,823)	-	38,987
Corporate income tax	(5,105)	-	_	-	(5,105)
Corporate vehicle transport tax	-	256	(256)	-	-
TT 1 . 1 .	107	1 471	(1 101)		117

127

239

116,232

121,343

(5,111)

(6)

1,471

1,605

5,263 **1,399,576** 

Unemployment duty

Natural resources tax

Real estate tax

Total, including

due to the budget overpayment

(1,481)

(5,263)

(1,406,963)

(983)

117

861

108,845

113,956

(5,111)

(6)

#### 17. OTHER PAYABLES

	2013	2012
	EUR	EUR
Salaries	136,035	141,700
Trade union	174	913
Deposited salary	1,245	485
Total	137,454	143,098
18. NET SALES		
	2013	2012
	EUR	EUR
Medical ambulant services	3,294,993	3,404,850
Medical hospital services	909,783	989,098
Insurance payments	321,414	301,448
VS ZDC ambulant services	278,847	228,966
Inpatient Care	153,772	280,575
Stomatology services	52,833	64,526
Family doctors	31,868	39,557
Residents training	20,859	37,110
Ms registra uzturesana	13,144	13,144
Other income	3,961	32,467
Total	5,081,474	5,391,741

#### 19. COST OF GOODS SOLD

17. COST OF GOODS SOLD		
	2013	2012
	EUR	EUR
Salaries and wages	2,232,465	2,162,573
Fixed assets depreciation	676,843	685,298
Medical goods	636,675	677,331
Social tax	524,391	507,844
Public utilities	249,382	254,654
VAT - expenses	245,431	317,670
Repair expenses	153,499	194,499
Current assets write-off	61,077	84,796
Security expenses	40,014	33,867
Uzkrājumi atvaļinājumiem	38,536	(50,493)
Feeding expenses	31,639	38,349
Computer maintenance, repair	27,908	25,661
Household goods	26,007	30,945
Medical researches	38,583	25,441
Office expenses	11,315	9,446
Transport expense	9,182	9,508
Annual payment to the stock exchange	7,114	7,114
Advertising	6,511	17,850
ERP system maintanance	6,229	4,886
Insurance expenses	5,949	4,833
Real estate tax	5,263	5,263
Accruals for doubtful debts	4,010	(2,709)
Employees trainings	2,942	9,606
Unemployment duty	1,473	1,477
Allowances to employees	1,281	1,707
Gifts to employees	710	847
Rent of equipment	569	-
Received discounts	(8,580)	(14,644)
Other operating expenses	72,716	88,362
Total	5,109,134	5,131,981

#### 20. ADMINISTRATIVE EXPENSES

	2013 EUR	2012 EUR
Salaries and wages	247,205	260,179
Social tax	58,213	61,183
Board remuneration	36,259	30,041
Board chairperson remuneration	30,977	31,117
Council members remuneration	19,123	19,123
Communication expenses	11,807	15,181
Audit expenses	7,114	7,114
Council chairperson remuneration	8,196	8,196
Board members social tax	7,499	6,285
Chairperson of the Board social tax	7,463	7,496
Office expenses	6,759	8,174
Bank expenses	5,849	5,646
Council members social tax	4,118	4,135
Administrative expenses	2,819	2,730
Legal services	1,975	1,976
Presentation expenses	1,615	2,927
Other administrative expenses	2,001	2,234
Total	458,992	473,737
21. OTHER OPERATING INCOME		
	2013	2012
	EUR	EUR
Rent income	95,823	72,645
ERAF income: fixed assets depreciation	47,551	29,015
Hotel services – food	15,360	17,554
Utilities for tenants	6,076	14,139
Net gain from sale of fixed assets	3,695	-
Laundry income	1,005	1,225
Solarium income	512	679
Other income	7,716	14,573
Total	177,738	149,830
22. OTHER OPERATING EXPENSES		
	2013	2012
	EUR	EUR
Penalties	30	511
Loss from fixed assets disposals	-	582
Other expenses	1,283	5,384
Total	1,313	6,477
23. INTEREST INCOME AND SIMILAR I	NCOME	
	2013	2012
	EUR	EUR
Interest income	-	38
Ieņēmumi no līdzdalības koncerna meitas un		
asociēto sabiedrību kapitālos	-	11,022
Total	<u> </u>	11,060
24. CORPORATE INCOME TAX		
	2012	2012
	2013 EUD	2012 EUD
Calculated Cornorate income toy	EUR	EUR
Calculated Corporate income tax Deferred Corporate income tax	(15,374)	17,181
Total	$\frac{(15,374)}{(15,374)}$	17,181
	1,,	17,101

24. CORPORATE INCOME TAX (CONTINU	JED)	
`	2013	2012
	EUR	EUR
Profit (loss) before tax	(441,413)	(84,752)
Theaoretically calculated corporate income tax,		
rate 15%	(66,212)	(12,713)
Permanent differencies	7,574	7,574
Calculated corporate income tax	<u>-</u>	<u> </u>
Deffered tax		
Temporary difference between financial statement depreciation and depreciation for tax		
purposes	(686,233)	(536,813)
Temporary difference of fixed assets		
revaluation	(163,184)	(539,759)
Accruals for vacations	107,711	69,176
Total temporary differencies	(741,706)	$\overline{(1,007,396)}$
Tax rate applied	15%	15%
Deferred tax liabilities	111,256	151,109

#### 25 Transactions with related parties

Recognized deferred tax liabilities

In the Year 2013, there has been one transactions with the related party: loan for real estate tax payment (See Note 8).

111,256

#### **26** Contingent laibilities

Management of the Company is not aware of any guarantees issued, court cases and other contingencies that could affect the Company's financial condition as on December 31, 2013.

151,109